DotLab shares key market research findings for its new DotEndo™ test

Findings underscore the need to democratize and expand access to clinical diagnosis of endometriosis

NEW YORK, October 25, 2022 /PRNewswire/ — Today, DotLab shares key qualitative market research findings regarding receptivity and interest in the company’s new endometriosis diagnostics. The DotEndo™ test has been well received; most patients agreed that the test is relevant to their situation (86%), are interested in knowing more (96%), and would ask their OB/GYN about the test (84%). OB/GYNs and REIs surveyed expressed an unmet need for a reliable, widely available, and non-invasive test for endometriosis to triage patients to the appropriate treatment and/or specialists early on.

Symptoms of endometriosis clinically overlap with other conditions, often making it difficult to identify the disease. “It would be nice to have a [diagnosis] before proceeding with treatment, especially if it has side effects or potential morbidities,” said an OB/GYN who participated in the study.

Research indicates that if DotEndo™ has a low cost to the patient or is covered by insurance, doctors would use the test widely – and for the most part, DotEndo™ would be part of the initial workup. Similarly, nearly all patients said they would be interested in the test if it was within their desired price range, and 89% would pursue the test if it was covered by their insurance.

The research, carried out by a third party, was conducted on a sample of patients aged 18 to 49 (n = 800). Patients had >US$50,000 annual household income and were either fertility patients (n=399) currently seeking fertility treatments such as IVF or IUI, symptomatic patients (n=401) or without a diagnosis of endometriosis (n=201 ) or with a suspected or confirmed diagnosis of endometriosis (n=200). Primary market research interviews with 25 relevant providers were also included: 14 obstetricians/gynaecologists and 11 reproductive endocrinology and infertility (REI) specialists.

Patient Caitlin Hale, who was not involved in the research, said, “In hindsight, a prior diagnosis of endometriosis would have saved my family and me years of pain, confusion and financial stress.” She added that a non-invasive test could “transform the lives of patients with endometriosis by eliminating diagnostic delays and eradicating the normalization and stigmatization of menstrual pain.”

Through its technology, DotLab seeks to reduce the disparity of care for patients with endometriosis and shorten today’s decade-long diagnostic odyssey, opening the door to empirical treatment and appropriate referral.

About Dot Lab

Dot Laboratories, Inc. (“DotLab”) is a women-founded, women-led company solving some of the world’s most significant diagnostic challenges through the latest advancements in multiomics and computational biology. The company delivers clinical innovations in areas of high unmet need. The company is leveraging its expertise with new cutting-edge biomarkers and the power of machine learning to provide non-invasive testing, starting with endometriosis. The company is driving a paradigm shift in disease identification and management.

Media Contact: [email protected]
General contact details: [email protected]

SOURCE DotLab

About Cecil Cobb

Check Also

Book talk: 3 entertaining crime novels

Jeff Popple reviews three entertaining new crime novels from America. More of Jeff’s reviews can …